Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Apoptosis-based anticancer drugs

Nature Reviews Drug Discovery volume 1, pages 101–102 (2002)Cite this article

Public companies mentioned:

  • Aventis (AVE-$67.20)

  • Genta Inc. (GNTA-$15.03, OUTPERFORM)

  • Introgen Therapeutics, Inc. (INGN-$5.09)

  • Onyx Pharmaceuticals, Inc. (ONXX-$4.98)

  • Pfizer Inc. (PFE-$41.40)

  • Schering-Plough Corp. (SGP-$36.11)

Aventis (AVE-$67.20)

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Jansen, B. et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356, 1728–1733 (2000).

    Article  CAS  Google Scholar 

  2. Clayman, G. L. et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 16, 2221–2232 (1998).

    Article  CAS  Google Scholar 

  3. Swisher, S. G. et al. Induction of pro-apoptotic mediators and tumor regression following intratumoral delivery of adenoviral p53 (RPR/INGN201) and radiation therapy in patients with non-small-cell lung cancer. Proc. Am. Soc. Clin. Oncol. 20, A1024 (2001).

    Google Scholar 

  4. Buller, R. E. et al. Multi-dose intraperitoneal (IP) RAD/p53 (SCH58500) gene replacement combined with chemotherapy in heavily pretreated recurrent ovarian cancer is associated with prolonged survival. Proc. Am. Soc. Clin. Oncol. 20, A1047 (2001).

    Google Scholar 

  5. Khuri, F. R. et al. A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature Med. 6, 879–885 (2000).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Analyst in Biopharmaceuticals at Stephens Inc., 111 Center Street, Little Rock, 72201, Arkansas, USA

    Jason Y. Zhang

Authors
  1. Jason Y. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Related links

Related links

DATABASES

LocusLink

BCL2

TP53

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, J. Apoptosis-based anticancer drugs. Nat Rev Drug Discov 1, 101–102 (2002). https://doi.org/10.1038/nrd742

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd742

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing